Editorial Polices

 

Peer Review Process

Fitofarmaka: Jurnal Ilmiah Farmasi applies a double-blind review system in which the author and reviewers do not recognise each other, and their identity is maintained to be confidential. Reviewers are obliged to declare when they found that the article that they are assigned might have any potential conflict of interest. We attempt to complete the article review and processing in 4-12 weeks after submission. The submitted articles will undergo screening and review processes below:

  1. Author’s submission (letter of submission to be issued)
  2. Technical check by administrator (i.e., supporting document completeness)
  1. The submitted manuscripts must fulfill scientific merit or novelty appropriate to the focus and scope of this journal. (Focus and Scope)
  2. Writing style, formatting style such as the title, authors, affiliations, keywords, main text, all tables and figures, and citation style (Author Guideline)
  3. For checking Plagiarism, Editorial Boards will screen plagiarism using Turnitin Software maximum 20%. If it is found plagiarism indication, editorial board will reject manuscript immediately (letter of permanent rejection to be issued).
  1. Editorial consideration after the technical check (i.e., writing style, formatting style, referencing, topic appropriateness, plagiarism check), decision:
  1. Pass/Appropriate, then go to step 4 
  2. Fail/Inappropriate, then REJECTED, to be revised and re-submit (letter of rejection including revision suggestions to be issued) OR final rejection  (letter of permanent rejection to be issued)
  1. First Round Peer Review, double-blind (i.e., the appointment of two reviewers by the section editor, review process and results in the levels of criteria). Peer review results:
  1. Both reviewers recommend for rejection (level 5), then go to step 5a
  2. Both reviewers recommend for acceptance with major (level 4) or minor (level 3) revision, then go to step 5b
  3. Both reviewers recommend for acceptance with revision by editors (level 2) or without revision (level 1), then go to step 5c 
  4. Conflicting recommendations, one reviewer suggests for level 3-4 acceptance, and the other suggests for level 1-2 acceptance, then go to step 5d
  5. Conflicting recommendations, one reviewer suggests for rejection (level 5), and the other suggests for acceptance (level 1-4), then go to step 5e
  1. Editorial consideration after review, decision:
  1. Submission is rejected (letter of permanent rejection to be issued, including reviewers’ and editor’s suggestions)
  2. Submission is sent back to the author (letter of revision request to be issued, including reviewers’ and editor’s suggestions)
  3. Submission is accepted for publication (letter of acceptance to be issued, the corresponding author to fulfil all administrative requirements), then go to step 7
  4. Editorial board’s discretion and decision to be sent back to the author (letter of revision request to be issued, including reviewers’ and editor’s suggestions) OR to be accepted for publication (letter of acceptance to be issued, corresponding author to fulfil all administrative requirements), then go to step 7
  5. Editorial board’s discretion and decision à to be assigned to a third reviewer (go to step 6) OR to be sent back to the author for revision with editor’s suggestion (letter of revision request to be issued, including reviewers’ and editor’s suggestions)
  1. Second Round Peer Review, by a third reviewer, results:
  1. A third reviewer recommends for rejection (level 5), then go to step 5a
  2. A third reviewer recommends for acceptance (level 1-4), then go to step 5c
  1. Lay-outing by the editorial team
  2. Proofreading by the corresponding author
  3. Article final lay-outing and finalisation
  4. Article to be published

 

Publication Frequency

FITOFARMAKA: Jurnal Ilmiah Farmasi with e-ISSN is 2622-755X and p-ISSN is 2087-9164. It is published 2 times a year (every June and December). It is a peer-reviewed journal and publishes original and review articles in English.

 

Open Access Policy

This journal is an open-access journal that provides immediate, worldwide, barrier-free access to the full text of all published articles without charge readers or their institutions for access. Readers have the right to read, download, copy, distribute, print, search, or link to the full texts of all articles in Fitofarmaka: Jurnal Ilmiah Farmasi. This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

 

Publication Ethics

FITOFARMAKA: Jurnal Ilmiah Farmasi (FJIF) follows guidelines from Committee on Publication Ethics (COPE) in facing all aspects of publication ethics and, in particular, how to handle cases of research and publication misconduct. All articles in this journal involving human subjects should respect principles of research ethics as described in Declaration of Helsinki and studies involving animals should obey the ARRIVE and Guide for the Care and Use of Laboratory Animals.

FJIF adapts COPE to meet high quality standard of ethics for publisher, editors, authors, and reviewers. As an essential issue, publication ethics needs to be explained clearly to improve the quality of the research worldwide. In this part, we explain the standard for editors, authors, and reviewers. In addition, publisher don't have right to interfere with the integrity of the contents and only support to publish in timely manner.

Standards for Authors:

  1. The author ensures that the material to be published have not been published and sent to another place simultaneously.
  2. Authors must ensure the authenticity of their research and they have cited the others opinions correctly in accordance with the reference format.
  3. The author is not involved in plagiarism.
  4. 'Salami' publication is prohibited in FJIF.
  5. Authors must follow the criteria described in the writing guideline for the authors of FJIF.
  6. Authors are not advised to publish any personal information that may make identity of the patient recognizable in the form of the description section, photograph or genealogy. If photographs of patients are very important and indispensable as scientific information, the authors should have received approval in written form and has clearly stated it.
  7. In the case of experiments on humans, the authors state that the study was in accordance with the ethical standards of the Helsinki declaration, which leads the human experiment. If there are doubts raised whether the study took place in accordance with the declaration, the author should explain it. In the case of experiments on animals, the author has certified that the author has followed the guidelines and abroad with regard to animal experiments in the laboratory.
  8. Authors must submit the data and details to the editor, if suspected falsification or fabrication of data.
  9. The authors should explain everything that can give rise to a conflict of interest such as employment, research costs, consulting fees, and intellectual property on guidelines for FJIF authors.

Standards for Editors:

  1. The Editor is responsible for every article published in FJIF.
  2. Editor helps the authors follow the guidelines for authors.
  3. The editors may communicate with other editors or reviewers in making a final decision.
  4. Editor assess the manuscript publication objectively, regardless the author's racial background, religion, gender, seniority, ethnicity, political beliefs, institutional affiliation or nationality. The editor must relinquish his/her duties if there is a potential conflict of interest.
  5. The Editor must ensure that the document which is sent to the reviewers do not contain information on the author and vice versa.
  6. The editor's decision must be notified to the author along with the reviewers' comments, except which contain offensive or libelous statements.
  7. Editors should respect the request of the author that the order is not subject to review by any other person for any reason.
  8. Editor and all staff must ensure the confidentiality of the submitted manuscript.
  9. If there is a suspicion of error or dispute in writing, Editor solves it by using the COPE as guide.

Standards for Reviewers:

  1. Reviewers need to comment on ethical questions and possible research and publication misconduct
  2. Reviewers will do the work in timely manner and should notify editor if they can not complete the work
  3. Reviewers need to keep the confidentiality of the manuscript
  4. Reviewers should not accept to review the manuscripts in which there is potential conflict of interest between them and any of the authors

 

Plagiarism Policy

FITOFARMAKA: Jurnal Ilmiah Farmasi Editorial board will screen plagiarism using Turnitin Program minimum 20% level of plagiarism. FITOFARMAKA: Jurnal Ilmiah Farmasi Editorial board recognizes that plagiarism is not acceptable and therefore establishes the following policy stating specific actions (penalties) when plagiarism is identified in an article that is submitted for publication in FITOFARMAKA: Jurnal Ilmiah Farmasi.

Definition: Plagiarism involves the "use or close imitation of the language and thoughts of another author and the representation of them as one's own original work."

Policy: Papers must be original, unpublished, and not pending publication elsewhere. Any material taken verbatim from another source needs to be clearly identified as different from the present original text by (1) indentation, (2) use of quotation marks, and (3) identification of the source.

Any text of an amount exceeding fair use standards (herein defined as more than two or three sentences or the equivalent thereof) or any graphic material reproduced from another source requires permission from the copyright holder and, if feasible, the original author(s) and also requires identification of the source; e.g., previous publication.

When plagiarism is identified, the Editor in Chief and Editor are responsible for the review of this paper and will agree on measures according to the extent of plagiarism detected in the paper in agreement with the following guidelines:

Level of Plagiarism

Minor: A short section of another article is plagiarized without any significant data or idea taken from the other paper

Action: A warning is given to the authors and a request to change the text and properly cite the original article is made

Intermediate: A significant portion of a paper is plagiarized without proper citation to the original paper

Action: The submitted article is rejected and the authors are forbidden to submit further articles for one year

Severe: A significant portion of a paper is plagiarized that involves reproducing original results or ideas presented in another publication

Action: The paper is rejected and the authors are forbidden to submit further articles for five years.

 

It is understood that all authors are responsible for the content of their submitted paper as they all sign the FITOFARMAKA: Jurnal Ilmiah Farmasi Copyright Transfer Form. If a penalty is imposed for plagiarism, all authors will be subject to the same penalty.

If a second case of plagiarism by the same author(s) is identified, a decision on the measures to be enforced will be made by the Editorial board (Editor-in-Chief, and Editorial members) with the Chair of the Editor in Chief. The author(s) might be forbidden to submit further articles forever.

This policy applies also to material reproduced from another publication by the same author(s). If an author uses text or figures that have previously been published, the corresponding paragraphs or figures should be identified and the previous publication referenced. It is understood that in case of a review paper or a paper of a tutorial nature much of the material was previously published.

The author should identify the source of the previously published material and obtain permission from the original author and the publisher. If an author submits a manuscript to FITOFARMAKA: Jurnal Ilmiah Farmasi with significant overlap with a manuscript submitted to another journal simultaneously, and this overlap is discovered during the review process or after the publications of both papers, the editor of the other journal is notified and the case is treated as a severe plagiarism case. Significant overlap means use of identical or almost identical figures and identical or slightly modified text for one half or more of the paper. For self plagiarism of less than one half of the paper but more than one tenth of the paper, the case shall be treated as intermediate plagiarism. If self plagiarism is confined to the methods section, the case shall be considered as minor plagiarism.

If an author uses some of his previously published material to clarify the presentation of new results, the previously published material shall be identified and the difference to the present publication shall be mentioned. Permission to republish must be obtained from the copyright holder. In the case of a manuscript that was originally published in conference proceedings and then is submitted for publication in FITOFARMAKA: Jurnal Ilmiah Farmasi either in identical or in expanded form, the authors must identify the name of the conference proceedings and the date of the publication and obtain permission to republish from the copyright holder. The editor may decide not to accept this paper for publication.

However, an author shall be permitted to use material from an unpublished presentation, including visual displays, in a subsequent journal publication. In the case of a publication being submitted that was originally published in another language, the title, date and journal of the original publication must be identified by the authors, and the copyright must be obtained. The editor may accept such a translated publication to bring it to the attention of a wider audience. The editor may select a specific paper that had been published (e.g. a “historic” paper) for republication in order to provide a better perspective of a series of papers published in one issue of FITOFARMAKA: Jurnal Ilmiah Farmasi. This republication shall be clearly identified as such and the date and journal of the original publication shall be given, and the permission of the author(s) and the publisher shall be obtained.

The FITOFARMAKA: Jurnal Ilmiah Farmasi layout editor for the Journal is responsible for maintaining the list of authors subjected to penalties and will check that no authors of a submitted paper are on this list. If a banned author is identified, the layout editor will inform the Editor-in-Chief who will take appropriate measures. This policy will be posted on the web site with the instructions for submitting a manuscript, and a copy will be sent to the authors with the confirmation email upon initial receipt of their original manuscript. A sentence shall be added to the copyright transfer form to indicate that the author(s) have read the Plagiarism Policy.

 

Correction and Retraction

In certain cases when there is a serious error or suspected violations, FITOFARMAKA: Jurnal Ilmiah Farmasi will publish a correction and retraction.


Correction
In the case of serious errors that affect the article by way of material (but not completely cancel the results), or significantly interfere with the reader's understanding or evaluation of the article, FITOFARMAKA: Jurnal Ilmiah Farmasi  publish corrections records related to the published article. This article is published will be left unchanged.

Retractions
In accordance with the “Retraction Guidelines” by the Committee on Publication Ethics (COPE) FITOFARMAKA: Jurnal Ilmiah Farmasi will retract a published article if

  • there is clear evidence that the findings are unreliable, either as a result of misconduct (e.g. data fabrication) or honest error (e.g. miscalculation),
  • the findings have previously been published elsewhere without proper crossreferencing, permission or justification (i.e. cases of redundant publication),
  • it constitutes plagiarism,
  • it reports unethical research.

An article which is pulled by issuing revocation notices associated with or replace the article withdrawn. FITOFARMAKA: Jurnal Ilmiah Farmasi will make every effort to clearly identify an article drawn like that.

If an investigation is underway which may result in the revocation of an article FITOFARMAKA: Jurnal Ilmiah Farmasi can choose to remind readers to publish an expression of concern.

 

Fair Play and Withdrawal

Fair Play

The editor evaluates the manuscripts for their intellectual content only without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors.

 

Withdrawal of Manuscripts

The author is not permitted to withdraw the submitted manuscript because withdrawal is a waste of valuable resources that the editor has spent in processing the manuscript. If the author still requests for withdrawal of the manuscript when the manuscript is still under the peer-reviewing process or has been accepted for publications, the author will be restricted for publicarion in Fitofarmaka: Jurnal Imliah Farmasi for 2 years, as a withdrawal penalty.

 

Publication Fee

Start from July 2020, for service improvement, FITOFARMAKA: Jurnal Ilmiah Farmasi charge the article publication fee for supporting the cost of wide open access dissemination of research results, managing the various costs associated with handling and editing of the submitted manuscripts, and the Journal management and publication in general, the authors or the author's institution is requested to pay a publication fee for each article accepted. 

Article Submission: 0.00 (IDR)
Authors are don't have to pay an Article submission Fee as part of the submission process.

Article Publication: 1.000.000 (IDR)

If this paper is accepted for publication, you will be asked to pay an Article Publication Fee to cover publications costs.

Payment is transferred through BNI Bank with 6010006053 in the name of Yayasan Pakuan Siliwangi Account, including proof of transfer

If you do not have funds to pay such fees, you will have an opportunity to waive each fee. We do not want fees to prevent the publication of worthy work.

 

Complaints

Any authors who may have grievances about any aspect of their interaction with the FJIF should e-mail the Editor-in-Chief at fitofarmaka@unpak.ac.id. Every effort will be made to acknowledge the complaint within 7 days of receiving it. If required the Editor-in-Chief will consult with other editors regarding the complaint. The Editor-in-Chief will liaise directly with the complainant and thoroughly explain the steps they have taken to resolve the matter..